PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-2.80%
Revenue decline while Drug Manufacturers - Specialty & Generic median is 1.14%. Seth Klarman would investigate if market share loss is temporary.
9.66%
Cost increase while Drug Manufacturers - Specialty & Generic shows cost reduction. Peter Lynch would examine competitive disadvantages.
-41.28%
Gross profit decline while Drug Manufacturers - Specialty & Generic median is 6.55%. Seth Klarman would investigate competitive position.
-39.59%
Margin decline while Drug Manufacturers - Specialty & Generic median is 0.84%. Seth Klarman would investigate competitive position.
89.29%
R&D change of 89.29% versus flat Drug Manufacturers - Specialty & Generic spending. Walter Schloss would verify adequacy.
-7.89%
G&A reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate efficiency gains.
26.17%
Marketing expense change of 26.17% versus flat Drug Manufacturers - Specialty & Generic spending. Walter Schloss would verify adequacy.
-1405.27%
Other expenses reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
-25.42%
Operating expenses reduction while Drug Manufacturers - Specialty & Generic median is 0.84%. Seth Klarman would investigate advantages.
-2.94%
Total costs reduction while Drug Manufacturers - Specialty & Generic median is -0.33%. Seth Klarman would investigate advantages.
-1.25%
Interest expense reduction while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate advantages.
4.09%
D&A growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.07%. Jim Chanos would check for overinvestment.
-774.69%
EBITDA decline while Drug Manufacturers - Specialty & Generic median is 7.22%. Seth Klarman would investigate causes.
86.17%
EBITDA margin growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.46%. Joel Greenblatt would investigate advantages.
20.03%
Operating income growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 9.94%. Joel Greenblatt would investigate advantages.
17.73%
Operating margin growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.40%. Joel Greenblatt would investigate advantages.
145.72%
Other expenses growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 1.37%. Jim Chanos would check for issues.
-117.61%
Pre-tax income decline while Drug Manufacturers - Specialty & Generic median is 12.05%. Seth Klarman would investigate causes.
-123.88%
Pre-tax margin decline while Drug Manufacturers - Specialty & Generic median is 9.46%. Seth Klarman would investigate causes.
15.06%
Tax expense growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.16%. Jim Chanos would check for issues.
-89.15%
Net income decline while Drug Manufacturers - Specialty & Generic median is 13.54%. Seth Klarman would investigate causes.
-94.61%
Net margin decline while Drug Manufacturers - Specialty & Generic median is 10.35%. Seth Klarman would investigate causes.
-78.84%
EPS decline while Drug Manufacturers - Specialty & Generic median is 16.97%. Seth Klarman would investigate causes.
-78.84%
Diluted EPS decline while Drug Manufacturers - Specialty & Generic median is 16.67%. Seth Klarman would investigate causes.
3.24%
Share count reduction below 50% of Drug Manufacturers - Specialty & Generic median of 0.15%. Jim Chanos would check for issues.
3.24%
Diluted share reduction below 50% of Drug Manufacturers - Specialty & Generic median of 0.10%. Jim Chanos would check for issues.